Effect of FAK inhibitor VS‐6063 (defactinib) on docetaxel efficacy in prostate cancer

Background Docetaxel, the standard chemotherapy for metastatic castration‐resistant prostate cancer (CRPC) also enhances the survival of patients with metastatic castration‐sensitive prostate cancer (CSPC) when combined with androgen‐deprivation therapy. Focal Adhesion Kinase (FAK) activation is a m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate 2018-03, Vol.78 (4), p.308-317
Hauptverfasser:	Lin, Hui‐Ming, Lee, Brian Y., Castillo, Lesley, Spielman, Calan, Grogan, Judith, Yeung, Nicole K., Kench, James G., Stricker, Phillip D., Haynes, Anne‐Maree, Centenera, Margaret M., Butler, Lisa M., Shreeve, S. Martin, Horvath, Lisa G., Daly, Roger J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Apoptosis Cancer therapies Castration chemoresistance Chemotherapy defactinib Docetaxel Explants Focal adhesion kinase Immunoblotting Immunohistochemistry Metastases Metastasis Prostate cancer Tumors VS‐6063 Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!